文献速递骨软组织肉瘤与黑色素瘤

SOX10在前哨淋巴结黑色素瘤转移检测中与S100蛋白特异性相当

SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment.
PubMed 文献 · Eur J Cancer · 2020-08-08

93.2%双阳性,SOX10在淋巴结免疫细胞不表达,判读争议更少。结论:SOX10检测淋巴结黑色素瘤转移的特异性与pS100相当,且判读可重复性高,推荐用于前哨淋巴结评估。

要点

  • SOX10检测淋巴结黑色素瘤转移特异性与pS100相当。
  • SOX10不表达于淋巴结免疫细胞,判读争议更少。
  • SOX10判读在不同中心与病理医生间可重复性高。

核心结论

  • SOX10检测淋巴结黑色素瘤转移的特异性与pS100相当,且判读可重复性高,推荐用于前哨淋巴结评估。

研究设计与样本

  • 切片数字化后由经验丰富的黑色素瘤病理医生小组共享评估。

主要发现

  • 绝大多数黑色素瘤对pS100和SOX10双阳性,占93.2%。
  • 少数病例(3.9%)为双阴性黑色素瘤。
  • 存在标志物不一致:1.9%为pS100(-)/SOX10(+),0.75%为pS100(+)/SOX10(-)。
  • SOX10在淋巴结免疫细胞类型中不表达,判读争议更少。

关键数值与推荐

  • SOX10检测淋巴结黑色素瘤转移的特异性与pS100相当。
  • SOX10判读在不同中心与不同病理医生间高度可重复。

临床怎么用

  • 前哨淋巴结评估中可选用SOX10免疫组化检测黑色素瘤转移。
  • SOX10因免疫细胞不着色,有助于减少判读争议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sentinel lymph node (SLN) biopsy remains crucial for melanoma staging. The European Organisation for Research and Treatment of Cancer Melanoma Group recommends performing immunohistochemical stainings for reproducible identification of melanoma metastases. S100 protein (pS100) is a commonly used melanocytic antigen because of its high sensitivity in spite of relatively low specificity. SRY-related HMG-box 10 protein (SOX10) is a transcription factor characterising neural crest-derived cells. It is uniformly expressed mostly in the nuclei of melanocytes, neural, and myoepithelial cells. Pathologists sometimes prefer SOX10 as a melanoma marker, but it has not yet been investigated on a large-scale to confirm that it is reliable and recommendable for routine SLN evaluation. METHODS: Four hundred one treatment-naïve lymph node (LN) metastatic melanomas were included in high-density tissue microarrays and were assessed for the presence of SOX10 and pS100 by immunohistochemistry. The slides were digitalised, shared and evaluated by a panel of experienced melanoma pathologists. RESULTS: The vast majority of melanomas were double-positive for pS100 and SOX10 (93.2%); a small percentage of the cases (3.9%) were double-negative melanomas. Discordance between the two markers was observed: 1.9% pS100(-)/SOX10(+) and 0.75% pS100(+)/SOX10(-). SOX10 was not expressed by immune cell types in the LN, resulting in a less controversial interpretation of the staining. CONCLUSIONS: SOX10 is as equally specific as pS100 for the detection of melanoma metastases in LNs. The interpretation of SOX10 staining is highly reproducible among different centres and different pathologists because of the absence of staining of immune cells.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Szumera-Ciećkiewicz A, Bosisio F, Teterycz P, et al. SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment. Eur J Cancer. 2020. PMID: 32781392. doi:10.1016/j.ejca.2020.06.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。